3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Carcinoma, Non-Small-Cell Lung
15
Squamous Cell Carcinoma of Head and Neck
2
Lung Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Small Cell Lung Carcinoma
1
Resectable Non-small Cell Lung Cancer
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Nonsquamous Non-small Cell Lung Cancer
1
Non-Squamous Non-Small Cell Lung Cancer
1
Neoplasm Metastasis
1
Melanoma
1
Head and Neck Neoplasms
1
Glioma
1
Carcinoma, Renal Cell
1
Advanced Non-small Cell Lung Cancer
1
Interventions
pembrolizumab
72
Cisplatin
57
Cetuximab
38
Fluorouracil
25
Nivolumab
21
Radiotherapy
20
Carboplatin
19
Paclitaxel
14
Docetaxel
11
Cyclophosphamide
9
Gefitinib
8
fludarabine
7
durvalumab
7
zalutumumab
6
atezolizumab
6
Drug Therapy
6
Bleomycin
6
epacadostat
5
cemiplimab
5
Radiotherapy, Intensity-Modulated
5
Pemetrexed
5
Ipilimumab
5
Gemcitabine
5
Afatinib
5
spartalizumab
4
Standard of Care
4
Radiation
4
Injections
4
Immune Checkpoint Inhibitors
4
Fibroblast Growth Factor 7
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Head and Neck Neoplasms
×
Platinum Compounds
×
Clear all
NCT04428333
2024-10-09
INDUCE-4
GlaxoSmithKline
Phase 3
Terminated
117 enrolled
33 charts